D

Dr. Lal Path Labs Ltd.

LALPATHLABNSE
Market snapshot · 2026-08-11 00:56 UTC

₹1,954.00

+₹22.40 (+1.16%)

MARKET CAP

₹32.68K Cr

STOCK P/E

60.2x

52W HIGH

₹1,973.50

52W LOW

₹1,272.60

BOOK VALUE

₹150.21

EPS

₹32.45

ROE

—

SECTOR

Health Care

DEBT/EQUITY

7.83

VOLUME

2.91L

P/B RATIO

13.01x

PEG RATIO

2.14

Sector

Health Care

Themes

Hospitals & Diagnostic Centres
D
Dividend
S
Split
E
Earnings
₹1,931.60₹1,774.09₹1,616.59₹1,459.09₹1,301.58VolumeEDSDEEDDEAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Valuation Metrics

Trading 38.4% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.86). Confidence: 87%.

Live forward EPS implies next-12-month EPS of ₹43.39. Applying the stock's normalized valuation corridor produces a fair range of ₹1,688.74 to ₹2,054.95, with base value near ₹1,865.77 (-4.5% vs current price).

Forward Valuation Outlook

Live forward estimate anchored to the company's historical valuation corridor.

Inside normalized range

Forward EPS

₹43.39

Forward P/E

45.0x

Base Fair Value

₹1,865.77

Fair Range

₹1,688.74 - ₹2,054.95

Upside To Base

-4.5%

Estimate Source

Live forward EPS

Growth Estimate

+27.8%

P/E
Strongly Overvalued

5Y Average

41.50

Current

59.53

Overvalued

47.36

Undervalued

38.92

EV/EBITDA
Strongly Overvalued

5Y Average

27.51

Current

39.91

Overvalued

31.02

Undervalued

23.66

P/S
Strongly Overvalued

5Y Average

7.79

Current

11.31

Overvalued

8.79

Undervalued

6.70

Peers & Comparison

Sector: Health Care · Theme: Hospitals & Diagnostic Centres

Hospitals & Diagnostic Centres Peers8 peers
Avg P/E: 83.4x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
NARAYANA HRUDAYALAYA LTD.
NHHospitals & Diagnostic Centres
+80.4%9.0%
45.3x
Undervalued
-46% vs avg
+6.8%
GLOBAL HEALTH LIMITED
MEDANTAHospitals & Diagnostic Centres
+26.5%11.9%
71.4x
Fair
-14% vs avg
+4.9%
FORTIS HEALTHCARE LTD
FORTISHospitals & Diagnostic Centres
+17.5%11.0%
68.7x
Undervalued
-18% vs avg
+3.7%
METROPOLIS HEALTHCARE LTD
METROPOLISHospitals & Diagnostic Centres
+16.6%11.8%
58.8x
Undervalued
-29% vs avg
+10.2%
JUPITER LIFE LINE HOSP L
JLHLHospitals & Diagnostic Centres
+18.2%12.0%
55.8x
Undervalued
-33% vs avg
+11.3%
ASTER DM QUALITY CARE LTD
ASTERDMHospitals & Diagnostic Centres
+21.6%6.5%
140.5x
Premium
+68% vs avg
+47.9%
KRISHNA INST OF MED SCI L
KIMSHospitals & Diagnostic Centres
+35.3%4.8%
160.4x
Premium
+92% vs avg
+11.6%
APOLLO HOSPITALS ENTER. L
APOLLOHOSPHospitals & Diagnostic Centres
+18.1%7.7%
66.0x
Undervalued
-21% vs avg
+23.2%
WHY THESE PEERS

DR. LAL PATH LABS LTD. trades at a discount (60.2x vs peer avg 83.4x), suggesting potential undervaluation relative to the Hospitals & Diagnostic Centres cohort. Peers include NARAYANA HRUDAYALAYA LTD., GLOBAL HEALTH LIMITED, FORTIS HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹764 CrJun 2026

Latest net profit

₹166 CrJun 2026

Latest EPS

₹9.90Jun 2026

Net margin

31.0%Jun 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.0%8.0%16.0%24.0%32.0%0.00 Cr200 Cr400 Cr600 Cr800 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.00 Cr200 Cr400 Cr600 Cr800 Cr₹0₹3₹6₹9₹12
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherNet Profit0.00 Cr200 Cr400 Cr600 Cr800 Cr

Latest reported period: Jun 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260.00 Cr800 Cr1.60K Cr2.40K Cr3.20K Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +480532476521574631569577641700632675764
Expenses +344369346383413437418418457484458494526
Operating Profit136163130138161194151159183215174182238
OPM %28%31%27%26%28%31%27%28%29%31%27%27%31%
Other Income +15141516312431252623-43730
Interest7766665545766
Depreciation18191935333334353338404340
Profit before tax125151120113154179144145172195123170222
Tax %25%25%26%29%26%28%27%-2%25%25%25%17%25%
Net Profit +94113888111412910514812914692141166
EPS in Rs5.616.775.294.846.867.716.308.887.718.695.508.429.90
Raw PDF

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

HolderJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters +53.79%53.21%53.21%53.21%53.19%
FIIs +21.69%21.86%20.29%17.18%17.35%
DIIs +17.62%18.22%19.20%21.37%21.59%
Government +0.29%0.27%0.01%0.01%0.01%
Public +6.22%6.07%6.94%7.88%7.48%
Others0.39%0.37%0.35%0.35%0.38%
Jun 2026
Promoters +
FIIs +
DIIs +
Government +
Public +
Others

Events Timeline

Annual Report FY26

FY2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Aug 06, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Jul 30, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Change in Directorate

Jul 26, 2026PDFCompany Reports Open

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Jul 25, 2026PDFCompany Reports Open